Table 2.
Characteristics of the patients with CRPA and CSPA before and after PSM.
| Baseline Characteristics | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| CSPA | CRPA | p-Value | CSPA | CRPA | p-Value | |
| Number of inpatient, n | 2674 | 1244 | 1155 | 1155 | ||
| Age in years, median (range) | 73 (0–100) | 79 (0–98) | <0.0001 | 77 (0–100) | 79 (0–98) | 0.994 |
| Sex male, n (%) | 1775 (66.38) | 877 (70.50) | 0.01 | 803 (69.52) | 812 (70.30) | 0.683 |
| Insurance, n (%) | 2322 (86.84) | 1084 (87.14) | 0.794 | 1007 (87.19) | 1007 (87.19) | 1.000 |
| Number of diagnosis, median (range) | 6 (1–36) | 7 (1–21) | 0.002 | 7 (1–36) | 7 (1–21) | 0.444 |
| Charlson comorbidity index, median (range) | 5 (1–34) | 5 (1–22) | 0.007 | 5 (1–34) | 5 (1–22) | 0.468 |
| Admission to ICU, n (%) | 282 (10.55) | 283 (22.75) | <0.0001 | 252 (21.82) | 221 (19.13) | 0.110 |
| Surgery, n (%) | 554 (20.72) | 275 (22.11) | 0.322 | 272 (23.55) | 245 (21.21) | 0.178 |
| Myocardial infarction, n (%) | 65 (2.43) | 46 (3.70) | 0.026 | 40 (3.46) | 40 (3.46) | 1.000 |
| Congestive heart failure, n (%) | 504 (18.85) | 196 (15.76) | 0.019 | 192 (16.62) | 178 (15.41) | 0.427 |
| Peripheral vascular disease, n (%) | 24 (0.90) | 20 (1.61) | 0.05 | 19 (1.65) | 17 (1.47) | 0.737 |
| Cerebrovascular diseases, n (%) | 1360 (50.86) | 813 (65.35) | <0.0001 | 732 (63.38) | 735 (63.64) | 0.897 |
| Dementia, n (%) | 169 (6.32) | 86 (6.91) | 0.484 | 82 (7.10) | 85 (7.36) | 0.810 |
| Chronic pulmonary disease, n (%) | 1113 (41.62) | 292 (23.47) | <0.0001 | 268 (23.20) | 289 (25.02) | 0.307 |
| Connective tissue disease, n (%) | 55 (2.06) | 16 (1.29) | 0.092 | 17 (1.47) | 16 (1.39) | 0.861 |
| Mild liver disease, n (%) | 40 (1.50) | 23 (1.85) | 0.414 | 21 (1.82) | 22 (1.90) | 0.878 |
| Peptic ulcer disease, n (%) | 57 (2.13) | 37 (2.97) | 0.109 | 37 (3.20) | 33 (2.86) | 0.627 |
| Diabetes mellitus, n (%) | 614 (22.96) | 310 (24.92) | 0.179 | 309 (26.75) | 291 (25.19) | 0.393 |
| Diabetes mellitus with chronic complications, n (%) | 52 (1.94) | 23 (1.85) | 0.839 | 21 (1.82) | 22 (1.90) | 0.878 |
| Moderate to severe chronic kidney disease, n (%) | 191 (7.14) | 105 (8.44) | 0.153 | 93 (8.05) | 94 (8.14) | 0.939 |
| Hemiplegia, n (%) | 37 (1.38) | 21 (1.69) | 0.463 | 20 (1.73) | 20 (1.73) | 1.000 |
| Solid tumor without metastases, n (%) | 117 (4.38) | 59 (4.74) | 0.605 | 56 (4.85) | 50 (4.33) | 0.551 |
| Leukemia, n (%) | 21 (0.79) | 15 (1.21) | 0.199 | 13 (1.13) | 11 (0.95) | 0.682 |
| Malignant lymphoma, n (%) | 17 (0.64) | 8 (0.64) | 0.979 | 10 (0.87) | 8 (0.69) | 0.636 |
| Severe liver disease, n (%) | 23 (0.86) | 9 (0.72) | 0.658 | 11 (0.95) | 8 (0.69) | 0.490 |
| Metastatic tumor, n (%) | 70 (2.62) | 24 (1.93) | 0.19 | 24 (2.08) | 23 (1.99) | 0.883 |
CRKP: carbapenem resistant Pseudomonas aeruginosa, CSKP: carbapenem susceptible P. aeruginosa, PSM: propensity score matching, ICU: intensive care unit.